gsk1210151a has been researched along with romidepsin* in 1 studies
1 other study(ies) available for gsk1210151a and romidepsin
| Article | Year |
|---|---|
Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy.
The combined inhibition of histone deacetylases (HDAC) and the proteins of the bromodomain and extraterminal (BET) family have recently shown therapeutic efficacy against melanoma, pancreatic ductal adenocarcinoma, testicular, and lymphoma cancers in murine studies. However, in such studies, the role of the immune system in therapeutically controlling these cancers has not been explored. We sought to investigate the effect of the HDAC inhibitor romidepsin (RMD) and the BET inhibitor IBET151, both singly and in combination, on vaccine-elicited immune responses. C57BL/6 mice were immunized with differing vaccine systems (adenoviral, protein) in prime-boost regimens under treatment with RMD, IBET151, or RMD+IBET151. The combined administration of RMD+IBET151 during vaccination resulted in a significant increase in the frequency and number of Ag-specific CD8 Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Depsipeptides; Female; Heterocyclic Compounds, 4 or More Rings; Histone Deacetylase Inhibitors; Immunogenicity, Vaccine; Interleukin-6; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Receptors, Cell Surface | 2018 |